
Rise Nano's Spectraguard classified as exempt device
Rise Nano's Spectraguard classified as exempt device

Rise Nano's Spectraguard classified as exempt device
Algernon Health to open brain PET scanning clinic
Bausch + Lomb releases Elios results
Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd
Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement
Rise Nano Optics Announces FDA Class I Device Classification for SPECTRAGUARD(TM) Nano-Optic Lens Technology
Algernon to Open the First Brain Dedicated PET Scanning Clinic in the U.S. at the HCA Florida University Medical Office Building
Rakovina Therapeutics to Present New Data at the AACR Annual Meeting 2026 - World's Premier Cancer Research Forum
Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering
DRI Healthcare Trust closes $108.72M debenture offering
Well Health supports Ontario primary care record system
Arch Biopartners Announces St. Michael's Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide
Mindbio increases placement to $1.5-million
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2025
Aptose Biosciences garners ISS nod for Hanmi deal